Cg Oncology Inc (CGON) 13F Positioning & Ownership Changes (Q2 2026)

CGON ranks #2618 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CGON is a top-conviction position for Decheng Capital LLC — at 61.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CGON belongs to Rtw Investments, LP, but the position matters far more to Decheng Capital LLC, who has 61.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Rtw Investments, LP has added to its CGON position for two straight quarters, increasing it by $521.4M to reach $605.0M today.

Pictet Asset Management Holding SA has trimmed its CGON position for two straight quarters, cutting it by $37.9M while still holding $18.1M.

CGON is down 1.7% today, but institutions show net buying of $1.1B this quarter — a divergence between today's price move and the underlying institutional flow.

CGON reported a net loss of $161.0M in its latest fiscal year.

• Not yet profitable — net loss of $161.0M in the latest fiscal year
• Revenue grew 254.7% year over year
• Net income declined year over year, from -$88.0M to -$161.0M
• Operating cash flow was negative, using $132.3M in cash
• Current ratio of 24.63x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.05x equity — within a conventional range